The Use of High-Volume Endorectal Balloon is Effective to Reduce Doses of Rectum and Bladder in ProstateCancer Patients Treated with Linac-Based StereotacticBody Radiotherapy

Independent samples t-tests were performed to examine the differences between the two groups.RESULTSThe mean dose given to the rectum was lower in the ERB group than in the non-ERB group, and a statistically significant dose reduction of 149.4 cGy per fraction was found in the ERB group (p

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:In this study, the effect of endorectal balloon (ERB) on risky organ doses was investigated in patients with low-medium risk prostate cancer treated with Stereotactic body radiotherapy (SBRT).METHODSIn the 17 patients, CT simulation and treatment was performed with an empty rectum and no ERB was used (non-ERB group).

📊

Temel Bulgular & Veri:ERB filled with 100-150 cc air into 15 patients was placed in the rectum and identified with the ERB group.

💡

Sonuç & Katkı:Independent samples t-tests were performed to examine the differences between the two groups.RESULTSThe mean dose given to the rectum was lower in the ERB group than in the non-ERB group, and a statistically significant dose reduction of 149.4 cGy per fraction was found in the ERB group (p

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

In this study, the effect of endorectal balloon (ERB) on risky organ doses was investigated in patients with low-medium risk prostate cancer treated with Stereotactic body radiotherapy (SBRT).METHODSIn the 17 patients, CT simulation and treatment was performed with an empty rectum and no ERB was used (non-ERB group). ERB filled with 100-150 cc air into 15 patients was placed in the rectum and identified with the ERB group. SBRT was performed to be delivered with volumetric modulated arc, with 10 FFF photon beams, using a linear accelerator with a high definition MLC. Dosimetric parameters for the rectum, bladder and penilbulb were compared between the two groups as a retrospective. Independent samples t-tests were performed to examine the differences between the two groups.RESULTSThe mean dose given to the rectum was lower in the ERB group than in the non-ERB group, and a statistically significant dose reduction of 149.4 cGy per fraction was found in the ERB group (p

🔖

Bu Makaleye Atıf Yap

GÜNDOĞ, M., BAŞARAN, H., ORHAN, O., YARAY, K., AKSÖZEN, T., KİRAZ, E., EROĞLU, C. (2022). The Use of High-Volume Endorectal Balloon is Effective to Reduce Doses of Rectum and Bladder in ProstateCancer Patients Treated with Linac-Based StereotacticBody Radiotherapy. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 4, 451–458. https://ajindex.com/articles/639183

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20(11):1531–43
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: prostate cancer. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/prostate.pdf. Accessed Aug 1, 2018
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375(15):1415–24
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2016;375(15):1425–37
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):17–24
De Los Santos J, Popple R, Agazaryan N, Bayouth JE, Bissonnette JP, Bucci MK, et al. Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery. Int J Radiat Oncol Biol Phys 2013;87(1):33–45
Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67(4):1099–105
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73(4):1043–8
Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011;6:3. 10.McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118(15):3681–90. 11.King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):877–